A novel thromboxane A2 receptor N42S variant results in reduced surface expression and platelet dysfunction

Summary

A small number of thromboxane receptor variants have been described in patients with a bleeding history that result in platelet dysfunction. We have identified a patient with a history of significant bleeding, who expresses a novel heterozygous thromboxane receptor variant that predicts an asparagine to serine substitution (N42S). This asparagine is conserved across all class A GPCRs, suggesting a vital role for receptor structure and function. We investigated the functional consequences of the TP receptor heterozygous N42S substitution by performing platelet function studies on platelet-rich plasma taken from the patient and healthy controls. We investigated the N42S mutation by expressing the wild-type (WT) and mutant receptor in human embryonic kidney (HEK) cells. Aggregation studies showed an ablation of arachidonic acid responses in the patient, whilst there was right-ward shift of the U46619 concentration response curve (CRC). Thromboxane generation was unaffected. Calcium mobilisation studies in cells lines showed a rightward shift of the U46619 CRC in N42S–expressing cells compared to WT. Radioligand binding studies revealed a reduction in BMax in platelets taken from the patient and in N42S–expressing cells, whilst cell studies confirmed poor surface expression. We have identified a novel thromboxane receptor variant, N42S, which results in platelet dysfunction due to reduced surface expression. It is associated with a significant bleeding history in the patient in whom it was identified. This is the first description of a naturally occurring variant that results in the substitution of this highly conserved residue and confirms the importance of this residue for correct GPCR function.

Keywords

Inherited / acquired platelet disorders - gene mutations - receptors - platelet pharmacology - platelet pathology / inherited - acquired

• References

• 1 Woodward DF, Jones RL, Narumiya S. International Union of Basic, Clinical Pharmacology. LXXXIII: classification of prostanoid receptors, updating 15 years of progress. Pharmacol Rev 2011; 63: 471-538.
• 2 Ting HJ, Murad JP, Espinosa EV. et al. Thromboxane A2 receptor: biology and function of a peculiar receptor that remains resistant for therapeutic targeting. J Cardiovasc Pharmacol Ther 2012; 17: 248-259.
• 3 Bousser MG, Amarenco P, Chamorro A. et al. Terutroban versus aspirin in patients with cerebral ischaemic events (PERFORM): a randomised, double-blind, parallel-group trial. Lancet 2011; 377: 2013-2022.
• 4 Kamae T, Kiyomizu K, Nakazawa T. et al. Bleeding tendency and impaired platelet function in a patient carrying a heterozygous mutation in the thromboxane A2 receptor. J Thromb Haemost 2011; 09: 1040-1048.
• 5 Hirata T, Kakizuka A, Ushikubi F. et al. Arg60 to Leu mutation of the human thromboxane A2 receptor in a dominantly inherited bleeding disorder. J Clin Invest 1994; 94: 1662-1667.
• 6 Mumford AD, Dawood BB, Daly ME. et al. A novel thromboxane A2 receptor D304N variant that abrogates ligand binding in a patient with a bleeding diathesis. Blood 2010; 115: 363-369.
• 7 Mumford AD, Nisar S, Darnige L. et al. Platelet dysfunction associated with the novel Trp29Cys thromboxane A(2) receptor variant. J Thromb Haemost 2013; 11: 547-554.
• 8 Watson S, Daly M, Dawood B. et al. Phenotypic approaches to gene mapping in platelet function disorders - identification of new variant of P2Y12, TxA2 and GPVI receptors. Hamostaseologie 2010; 30: 29-38.
• 9 Watson SP, Lowe GC, Lordkipanidze M. et al. Genotyping and phenotyping of platelet function disorders. J Thromb Haemost 2013; 11 (Suppl. 01) 351-363.
• 10 Smith SO. Structure and activation of the visual pigment rhodopsin. Annu Rev Biophys 2010; 39: 309-328.
• 11 Venkatakrishnan AJ, Deupi X, Lebon G. et al. Molecular signatures of G-protein-coupled receptors. Nature 2013; 494: 185-194.
• 12 Mundell SJ, Jones ML, Hardy AR. et al. Distinct roles for protein kinase C isoforms in regulating platelet purinergic receptor function. Mol Pharmacol 2006; 70: 1132-1142.
• 13 Mundell SJ, Luo J, Benovic JL. et al. Distinct clathrin-coated pits sort different G protein-coupled receptor cargo. Traffic 2006; 07: 1420-1431.
• 14 Pula G, Mundell SJ, Roberts PJ. et al. Agonist-independent internalisation of metabotropic glutamate receptor 1a is arrestin- and clathrin-dependent and is suppressed by receptor inverse agonists. J Neurochem 2004; 89: 1009-1020.
• 15 Nisar SP, Cunningham M, Saxena K. et al. Arrestin scaffolds NHERF1 to the P2Y12 receptor to regulate receptor internalisation. J Biol Chem 2012; 287: 24505-24515.
• 16 Lowe GC, Lordkipanidze M, Watson SP. et al. Utility of the ISTH bleeding assessment tool in predicting platelet defects in participants with suspected inherited platelet function disorders. J Thromb Haemost 2013; 11: 1663-1668.
• 17 Dawood BB, Lowe GC, Lordkipanidze M. et al. Evaluation of participants with suspected heritable platelet function disorders including recommendation and validation of a streamlined agonist panel. Blood 2012; 120: 5041-5049.
• 18 Adzhubei IA, Schmidt S, Peshkin L. et al. A method and server for predicting damaging missense mutations. Nat Methods 2010; 07: 248-249.
• 19 Choi Y, Sims GE, Murphy S. et al. Predicting the functional effect of amino acid substitutions and indels. PLoS One 07 2012; e46688.
• 20 Mumford A, Nisar S, Darnige L. et al. Platelet dysfunction associated with the novel Trp29Cys thromboxane A(2) receptor variant. J Thromb Haemost 2013; 11: 547-554.
• 21 FitzGerald GA. Mechanisms of platelet activation: thromboxane A2 as an amplifying signal for other agonists. Am J Cardiol 1991; 68: 11B-15B.
• 22 Perlman JH, Colson AO, Wang W. et al. Interactions between conserved residues in transmembrane helices 1, 2, and 7 of the thyrotropin-releasing hormone receptor. J Biol Chem 1997; 272: 11937-11942.
• 23 Michelsen K, Yuan H, Schwappach B. Hide and run. Arginine-based endoplasmic-reticulum-sorting motifs in the assembly of heteromultimeric membrane proteins. EMBO Rep 2005; 06: 717-722.
• 24 Cunningham MR, McIntosh KA, Pediani JD. et al. Novel role for proteinase-activated receptor 2 (PAR2) in membrane trafficking of proteinase-activated receptor 4 (PAR4). J Biol Chem 2012; 287: 16656-16669.
• 25 Fanelli F, Mauri M, Capra V. et al. Light on the structure of thromboxane A(2)receptor heterodimers. Cell Mol Life Sci 2011; 68: 3109-3120.
• 26 Mancia F, Assur Z, Herman AG. et al. Ligand sensitivity in dimeric associations of the serotonin 5HT2c receptor. EMBO Rep 2008; 09: 363-369.
• 27 Vassilakos A, Michalak M, Lehrman MA. et al. Oligosaccharide binding characteristics of the molecular chaperones calnexin and calreticulin. Biochemistry 1998; 37: 3480-3490.
• 28 Parent A, Roy SJ, Iorio-Morin C. et al. ANKRD13C acts as a molecular chaperone for G protein-coupled receptors. J Biol Chem 2010; 285: 40838-40851.